Natera (NasdaqGS:NTRA) announced a strategic expansion of its Board of Directors with the appointment of Monica Bertagnolli. This decision occurred against a backdrop of significant market volatility, ...

Shares of genetic testing company Natera (NASDAQ:NTRA). jumped 5.2% in the afternoon session after stocks rebounded, ...

RBC Capital analyst Conor McNamara initiated coverage of Natera (NTRA) with an Outperform rating and $251 price target The firm says Natera is ...

Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish ...

Natera has a twelve month low of $83.13 and a twelve month high of $183.00. The stock has a 50-day simple moving average of $165.61 and a two-hundred day simple moving average of $148.09.

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced the enrollment of the first patients in the HEROES clinical trial. HEROES is a multi-center ...

AUSTIN, Texas - Natera, Inc. (NASDAQ: NTRA), a healthcare diagnostics company with impressive revenue growth of 57% over the last twelve months and a market capitalization of $19 billion ...

The first patients have been enrolled in the HEROES trial, exploring de-escalation of anti-HER2 therapy in metastatic HER2+ ...

Shares of Natera stock opened at $140.66 on Wednesday. The stock has a market cap of $19.02 billion, a price-to-earnings ratio of -79.92 and a beta of 1.80. The company has a debt-to-equity ratio ...

HEROES is Natera's first clinical trial using Signatera to guide de-escalation of therapy in patients with metastatic HER2+ breast cancer Approximately 170 patients are expected to enroll in up to ...

GeneDx Holdings Corp. is delivering strong revenue growth, but it is still burning cash. Click here for more on WGS stock ...